The only drug approved to treat adrenal cortical cancer - Lysodren mitotane - is a derivative of DDT with severe side effects and pharmacokinetic challenges. Atterocor Inc. was spun out by the University of Michigan and is developing a compound that could be more efficacious, with an improved pharmacokinetic profile and better tolerability.

Adrenal cortical cancer (ACC) is a very rare and aggressive malignancy that affects the adrenal gland, which makes steroid hormones. About 500-600 patients are diagnosed annually in the U.S., with a similar incidence in Europe.